Cargando…

Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR ‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial

BACKGROUND: As the outcome of immunotherapy can be improved when concurrently or sequentially combined with cytotoxic chemotherapy or radiotherapy, we investigated the efficacy of immunotherapy maintenance following platinum‐based chemotherapy in epidermal growth factor receptor (EGFR)‐mutant non‐sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jiwon, Choi, Chang‐Min, Ji, Wonjun, Lee, Jae Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626224/ https://www.ncbi.nlm.nih.gov/pubmed/37699785 http://dx.doi.org/10.1111/1759-7714.15083

Ejemplares similares

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
por: Reville, Patrick K., et al.
Publicado: (2021)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials
por: Qiao, Lifen, et al.
Publicado: (2017)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
por: Ray, Paramita, et al.
Publicado: (2016)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma
por: Gigante, Elia, et al.
Publicado: (2022)

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
por: Hellmann, Matthew, et al.
Publicado: (2015)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
por: Hasegawa, Hirotaka, et al.
Publicado: (2022)

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment‐naive patients with advanced EGFR mutation‐positive non‐small cell lung cancer: Protocol of an open‐label, single‐arm phase II trial
por: Lee, Bora, et al.
Publicado: (2023)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
por: Hamanishi, Junzo, et al.
Publicado: (2021)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
por: Park, Keunchil, et al.
Publicado: (2021)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
por: Cansouline, Xavier, et al.
Publicado: (2022)

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Xia, Jinjing, et al.
Publicado: (2017)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f8jof2tt0aqrkrff79ukeortub